{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:34Z","timestamp":1787010334180,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    A 48-year-old man diagnosed with symptomatic metastatic medullary thyroid carcinoma (MTC) presented with dyspnea and a right neck mass which was identified as a metastatic lymph node. Despite initial treatments with sorafenib and chemotherapy, his condition continued to worsen. Evaluation using\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-FAPI-46 scintigraphy showed favorable uptake in both primary tumor and its metastases, leading to enrollment in a clinical trial for a combination therapy involving sorafenib and\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286. After four cycles of this treatment, the patient experienced significant improvement in symptoms, along with notable reductions in serum calcitonin and carcinoembryonic antigen (CEA) levels. This case underscores the potential effectiveness of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-FAPI-2286 in managing advanced MTC when conventional therapies prove ineffective.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005723","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:00:24Z","timestamp":1744858824000},"page":"e547-e550","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Combination Therapy With 177Lu-FAPI-2286 and Tyrosine Kinase Inhibitor: A Novel Approach for Treating Metastatic Medullary Thyroid Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Nasrin","family":"Raeisi","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Saber Tanha","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Ataei Azimi","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1007\/s00259-023-06348-4","article-title":"[68Ga]Ga-DOTA-FAPI-04 PET\/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET\/CT missed","volume":"50","author":"Al-Ibraheem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20250731","first-page":"241899","article-title":"177Lu]Lu-DOTAGA.FAPi dimer radionuclide therapy in patients with medullary thyroid cancer","volume":"65","author":"Bal","year":"2024","journal-title":"J Nuclear Med"},{"key":"R3-20250731","first-page":"P467","article-title":"Efficacy and safety of [177Lu]Lu-DOTAGA.FAPi dimer radionuclide therapy in patients with medullary thyroid cancer","volume":"64","author":"Bal","year":"2023","journal-title":"J Nuclear Med"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"1381863","DOI":"10.3389\/fmed.2024.1381863","article-title":"Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review","volume":"11","author":"Rizzo","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1097\/RLU.0000000000005469","article-title":"Variable tracer avidity and interlesional heterogeneity on 18F-FDG, 68Ga-DOTATATE, and 68Ga-DOTA-FAPi-04 PET\/CT imaging in a single individual patient with progressive metastatic medullary thyroid carcinoma","volume":"49","author":"Edamadaka","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/RLU.0000000000005259","article-title":"False-negative 68 Ga-FAPI PET\/CT in pediatric thyroid medullary carcinoma seen with 68 Ga-DOTATOC PET\/CT and 18 F-FDG PET\/CT","volume":"49","author":"Haidar","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12020-021-02800-3","article-title":"Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET\/CT","volume":"74","author":"Kuyumcu","year":"2021","journal-title":"Endocrine"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1089\/thy.2023.0008","article-title":"Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC positron emission tomography\/computed tomography imaging for the follow-up surveillance of patients with medullary thyroid cancer","volume":"33","author":"Ballal","year":"2023","journal-title":"Thyroid"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1097\/RLU.0000000000004051","article-title":"Fibroblast activation protein inhibitor imaging and therapy in a patient with multiple endocrine neoplasia type 2A syndrome","volume":"47","author":"Barashki","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:00:40Z","timestamp":1753938040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005723","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"2024-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}